Orexigen Therapeutics Patents
Orexigen Therapeutics has filed 35 patents.
Diabetes, Obesity, Abdomen, Syndromes, Rare diseases
Diabetes, Obesity, Abdomen, Syndromes, Rare diseases
When was Orexigen Therapeutics founded?
Orexigen Therapeutics was founded in 2002.
Where is Orexigen Therapeutics's headquarters?
Orexigen Therapeutics's headquarters is located at 3344 North Torrey Pines Court, La Jolla.
What is Orexigen Therapeutics's latest funding round?
Orexigen Therapeutics's latest funding round is Asset Sale.
How much did Orexigen Therapeutics raise?
Orexigen Therapeutics raised a total of $76M.
Who are the investors of Orexigen Therapeutics?
Investors of Orexigen Therapeutics include Nalpropion Pharmaceuticals, Kleiner Perkins Caufield & Byers, Domain Associates, Sofinnova Ventures, Scale Venture Partners and 7 more.
Who are Orexigen Therapeutics's competitors?
Competitors of Orexigen Therapeutics include Titan Pharmaceuticals, Gelesis, Euroclone SpA, BioMarck Pharmaceuticals, FORUM Pharmaceuticals, XenoPort, Telormedix, YM BioSciences, BrainCells, Allos Therapeutics and 22 more.
You May Also Like
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.
AngioChem is a clinical-stage biotechnology discovering and developing drugs that are capable of crossing the blood-brain barrier to treat brain diseases. The company's EPiC platform aims to solve the key problem for crossing the blood-brain barrier by developing drugs that use a receptor-based approach.
Telormedix is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company's lead product, TMX-101, is currently in a Phase II clinical trial for the treatment of CIS (carcinoma in situ) in the bladder. In addition, Telormedix is developing novel TLR7-targeted agonists. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. Telormedix also has a pipeline of programs for inflammatory and autoimmune diseases, which includes TMX-302, a TLR7-binding small molecule showing anti-inflammatory properties in vivo.
Dynogen is a biopharmaceutical company developing drugs for gastrointestinal (GI) and genitourinary (GU) disorders, including irritable bowel syndrome (IBS) and overactive bladder (OAB). Dynogen focuses on compounds that have previously been in the clinic and therefore have known safety and pharmacokinetic profiles.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.